دورية أكاديمية

Survival prognostic factors for patients with synchronous brain oligometastatic non-small-cell lung carcinoma receiving local therapy

التفاصيل البيبلوغرافية
العنوان: Survival prognostic factors for patients with synchronous brain oligometastatic non-small-cell lung carcinoma receiving local therapy
المؤلفون: Bai H, Xu J, Yang H, Jin B, Lou Y, Wu D, Han B
المصدر: OncoTargets and Therapy, Vol 2016, Iss Issue 1, Pp 4207-4213 (2016)
بيانات النشر: Dove Medical Press, 2016.
سنة النشر: 2016
المجموعة: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
مصطلحات موضوعية: non-small cell lung carcinoma, oligometatases, brain, stereotactic radiosurgery, surgery, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
الوصف: Hao Bai,1,* Jianlin Xu,1,* Haitang Yang,2,* Bo Jin,1 Yuqing Lou,1 Dan Wu,3 Baohui Han1 1Department of Pulmonary, 2Department of Pathology, 3Central Laboratory, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, People’s Republic of China *These authors contributed equally to this work Introduction: Clinical evidence for patients with synchronous brain oligometastatic non-small-cell lung carcinoma is limited. We aimed to summarize the clinical data of these patients to explore the survival prognostic factors for this population. Methods: From September 1995 to July 2011, patients with 1–3 synchronous brain oligometastases, who were treated with stereotactic radiosurgery (SRS) or surgical resection as the primary treatment, were identified at Shanghai Chest Hospital.Results: A total of 76 patients (22 patients underwent brain surgery as primary treatment and 54 patients received SRS) were available for survival analysis. The overall survival (OS) for patients treated with SRS and brain surgery as the primary treatment were 12.6 months (95% confidence interval [CI] 10.3–14.9) and 16.4 months (95% CI 8.8–24.1), respectively (adjusted hazard ratio =0.59, 95% CI 0.33–1.07, P=0.08). Among 76 patients treated with SRS or brain surgery, 21 patients who underwent primary tumor resection did not experience a significantly improved OS (16.4 months, 95% CI 9.6–23.2), compared with those who did not undergo resection (11.9 months, 95% CI 9.7–14.0; adjusted hazard ratio =0.81, 95% CI 0.46–1.44, P=0.46). Factors associated with survival benefits included stage I–II of primary lung tumor and solitary brain metastasis. Conclusion: There was no significant difference in OS for patients with synchronous brain oligometastasis receiving SRS or surgical resection. Among this population, the number of brain metastases and stage of primary lung disease were the factors associated with a survival benefit. Keywords: non-small-cell lung carcinoma, oligometastases, brain, stereotactic radiosurgery, surgery
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 1178-6930
العلاقة: https://www.dovepress.com/survival-prognostic-factors-for-patients-with-synchronous-brain-oligom-peer-reviewed-article-OTTTest; https://doaj.org/toc/1178-6930Test
الوصول الحر: https://doaj.org/article/50e8cc7e9422426d8f24f44ca4aed144Test
رقم الانضمام: edsdoj.50e8cc7e9422426d8f24f44ca4aed144
قاعدة البيانات: Directory of Open Access Journals